u/sock_puppet_spotter

Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.

Titration speed is a side-effect dial far more than an efficacy dial.

Origin to destination?

Not convinced. The evidence does not support that reading.

private prescription routes vary by region

Strongly agree. Step therapy is predictable if you have the criteria.

lane reports need origin, destination, carrier, actual transit days

the concentration on the vial in marker is the most important step

insulin and sulfonylurea interactions are real hypo risk

That is net peptide content, not purity. Different number, different meaning.

Inter-lab variance on this kind of assay is routinely 1–2 points. Different column, different gradient, different integration.

Rodent data is rodent data. Dose scaling is not linear and the models tell you what to investigate, not what to expect.

formulary exclusions are negotiable sometimes

Week 34 for me and the honest summary is: 17kg down, reflux manageable, and I have thought about food maybe four times today.

PDF metadata said the COA was created in a browser four months after the date printed on the page. Worth flagging.

Strongly agree. The dispute resolved and the record stayed updated.

copay is separate from coverage

Strongly agree. Customs adds unpredictable delay.

Every time this gets posted it hits the front page and every time someone has to re-explain it.

the carve-out clause varies by employer